Edgewise Therapeutics faces challenges with DMD/BMD programs, upcoming trial data concerns, and competitive risks.

Shares of biopharma outfit Edgewise Therapeutics (NASDAQ: EWTX) soared more than 50% today, reaching a three-year high following an update on the clinical testing of its cardiac drug EDG-7500.

Edgewise Therapeutics, Inc.’s EWTX share price has dipped by 5.98%, which has investors questioning if this is right time to buy.

April 2, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive top-line data of EDG-7500 from the Phase 2 ...

Edgewise Therapeutics is primarily focused on developing novel treatments for conditions such as Hypertrophic Cardiomyopathy (HCM), Duchenne Muscular Dystrophy (DMD), and Becker Muscular Dystrophy ...

May 8, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. (EWTX),, a leading muscle disease biopharmaceutical company, today reported financial results for the first quarter of 2025 and recent ...

In this article, we are going to take a look at where Edgewise Therapeutics, Inc. (NASDAQ:EWTX) stands against other top small cap stocks to buy with biggest upside potential. On April 24 ...

Edgewise Therapeutics is primarily focused on developing novel treatments for conditions such as Hypertrophic Cardiomyopathy (HCM), Duchenne Muscular Dystrophy (DMD), and Becker Muscular Dystrophy ...